摘要
晚期肺癌脑转移发生率高,预后差。近年来,随着肺癌总体治疗的发展,为晚期肺癌脑转移提供了更多的治疗手段和期待。目前的临床研究提示抗血管生成药物在肺癌脑转移的治疗中占有重要地位,从大分子的单克隆抗体,到泛靶点抗血管药物,再到小分子酪氨酸激酶抑制剂(Tyrosine kinase inhibitor,TKI),均显示出一定的疗效与良好的安全性,并与化疗、放疗以及表皮生长因子受体酪氨酸激酶抑制剂(Epidermal growth factor receptor tyrosine kinase inhibitor,EGFR-TKI)表现出良好的协同抗肿瘤作用。本文就抗血管生成药物治疗肺癌脑转移的研究新进展做一综述。
The incidence of brain metastases in advanced lung cancer is high and the prognosis is poor.In recent years,with the development of overall treatment for lung cancer,more treatments and expectations have been provided for advanced lung cancer with brain metastases.Current clinical studies suggest that antiangiogenic drugs play an important role in the treatment of lung cancer with brain metastasis including from monoclonal antibody to multi-target antiangiogenic drugs and then to small molecule tyrosine kinase inhibitor(TKI).These drugs have shown a certain efficacy and good safety,and they also show a significantly synergistic anti-tumor effect on chemotherapy,radiotherapy and epidermal growth factor receptor TKI(EGFR-TKI).This article reviews the new progress of anti-angiogenic drugs in the treatment of lung cancer with brain metastases.
作者
鲍瑜
朱立建(综述)
钱江(审校)
BAO Yu;ZHU Lijian;QIAN Jiang(Department of Oncology,People′s Hospital of Chizhou,Affiliated Chizhou Hospital of Anhui Medical University,Chizhou 247000,China)
出处
《实用肿瘤学杂志》
CAS
2021年第1期91-96,共6页
Practical Oncology Journal
关键词
抗血管生成
肺癌
脑转移
Antiangiogenesis
Lung cancer
Brain metastases
